Name	Hyungwoo Cho
Current Position & Affiliation	Assistant professor Department of Oncology Asan Medical Center, University of Ulsan College of Medicine, Korea
Country	South Korea
Major Field	Hematological malignancy (lymphoma, multiple myeloma)

Educational Background

2005. 3 – 2011. 2 M.D.
Chung-ang University, College of Medicine, Seoul, Korea

2014. 3 – 2016. 2. Master of Science
Postgraduate School
University of Ulsan College of Medicine, Seoul, Korea

2020. 3 – 2022.2 Ph.D. of Medicine
Postgraduate School
University of Ulsan College of Medicine, Seoul, Korea

Professional Experience

2020.3 – 2021.2 Full-time clinical instructor
Department of Oncology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea

2021.3 – Assistant Professor
Department of Oncology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea

Other Experience and Professional Memberships

Member of Korean Society of Hematology
Member of Korean Society of Medical Oncology
Member of American Society of Hematology

Member of International Myeloma Society

Main Scientific Publications

1. Minseung Suh, Jaewon Hyung, Chan-Sik Park et al, Prognostic significance of pretransplant 18F-FDG PET/CT metricsin relapsed/refractory diffuse large B-cell lymphoma with partialresponse to salvage chemotherapy prior to autologous stem celltransplantation, Br J Haematol, 2025
2. Minyoung Oh, Hyungwoo Cho, Ji Eun Park et al, Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT, Neuro-Oncology, 2024
3. Hyungwoo Cho, Kihyun Kim, Sang Eun Yoon et al, Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202), Hemasphere, 2024
4. Yunlin Zhang, Ruchi P. Patel, Ki Hyun Kim, Hyungwoo Cho et al, Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study, Molecular Cancer, 2024